Liberation Station Radio Show: August 3, 2021 Edition
Hour 1
|
Hour 2
|
Hour 1
|
Hour 2
|
Live video streams:
► https://www.facebook.com/wearechange.tampa/videos/178067387601531
► http://youtu.be/IfDyqcnzXzM?t=183
► https://www.facebook.com/wearechange.tampa/videos/178067387601531
► http://youtu.be/IfDyqcnzXzM?t=183
Guests
|
Frank Hopson spoke on what he's found: the CDC allows COVID PCR "tests" based on a "contrived samples." This is despite its announcement (www.cdc.gov/csels/dls/locs/2021/07-21-2021-lab-alert-Changes_CDC_RT-PCR_SARS-CoV-2_Testing_1.html) that it will wait until December 31, 2021 to withdraw its request for EUA (emergency use authorization) for the unreliable and inconclusive PCR "tests," the only "test" available through May 2020, driving the casedemic.
|
|
David Happe (anchor.fm/PiratePodcast, facebook.com/groups/PinellasWatch) spoke on efforts in Pinellas County and around Florida to prevent emergency measures in Pinellas County and mandatory masking in public schools, which would be in contravention of the recently-passed Florida Parents' Bill of Rights and Florida Governor Ron DeSantis' various executive orders.
|
Show Material
The next Pinellas County Commission Meeting is August 10, 8:30 AM, Florida Botanical Gardens, 12520 Ulmerton Rd, Largo, Florida.
Dr. Choe plans to address the Pinellas County Board of County Commissioners who are considering enacting a local emergency. This could include forced masking, expanded vaccine distribution (including schools) and other emergency powers. Come rally for MEDICAL HEALTH FREEDOM. Your liberty is being deliberated, and you need to prevent them from voting to restrict your freedom. We need people to rally at 8:30AM, and we need some people to go in and address the County Commission starting at 9:30AM"
Source: facebook.com/events/838310356818362
Frank Hopson wrote:
“You may have heard recently that the CDC has announced a change in the way it is testing for SARS-CoV-2:
'After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.' (Source: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data.)
The reason for the change is linked in the above announcement to this release by the FDA in late 2020 (emphasis mine):
'During the early months of the Coronavirus Disease 2019 (COVID-19) pandemic, clinical specimens [of the virus] were not readily available to developers of IVDs [in vitro diagnostics] to detect SARS-CoV-2. Therefore, the FDA authorized IVDs based on available data from ►CONTRIVED◄ samples generated from a range of SARS-CoV-2 material sources (for example, gene specific RNA, synthetic RNA, or whole genome viral RNA) for analytical and clinical performance evaluation. While validation using these ►CONTRIVED◄ specimens provided a measure of confidence in test performance at the beginning of the pandemic, it is not feasible to precisely compare the performance of various tests that used ►CONTRIVED◄ specimens because each test validated performance using samples derived from different gene specific, synthetic, or genomic nucleic acid sources.' (Source: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data.)
It goes on to say:
'From February through the middle of May, the FDA issued a total of 59 EUAs for IVDs for the qualitative detection of nucleic acid from SARS-CoV-2 based on validation data using ►contrived◄ specimens derived from SARS-CoV-2 viral RNA. As the pandemic progressed and more patient specimens became available, on May 11, 2020, the FDA recommended in the Policy for Coronavirus Disease-2019 Tests that developers obtain and use patient specimens to validate their tests.'
If you follow the link in that paragraph and go to page 18 of that non-binding policy paper, under '(2) Clinical Evaluation,' it says:
'The availability of positive samples has increased as the pandemic has progressed. As such, FDA now recommends that developers use positive clinical samples for clinical validation. Moreover, due to the increased availability of clinical samples, FDA recommends that developers confirm performance of their assay by testing a minimum of 30 positive specimens and 30 negative specimens as determined by an authorized assay. If you do not have access to clinical samples as determined by an authorized assay, ►CONTRIVED◄ clinical specimens may be considered. ►CONTRIVED◄ reactive specimens can be created by spiking RNA or inactivated virus into leftover clinical specimens, of which the majority can be leftover upper respiratory specimens such as NP swabs, or lower respiratory tract specimens such as sputum, etc. If ►CONTRIVED◄ samples are used, FDA recommends that twenty of the ►CONTRIVED◄ clinical specimens be spiked at a concentration of 1x2x LoD, with the remainder of specimens spanning the assay testing range. For this guidance, FDA defines the acceptance criteria for the performance as 95% agreement at 1x-2x LoD, and 100% agreement at all other concentrations and for negative specimens.' (Source: https://www.fda.gov/media/135659/download)
So after May 2020, ►contrived◄ samples were still allowed and will be allowed up until the last day of this year.
So what this is saying is the all COVID testing from February 2020 through May 2020 and however much testing until the end of the year is based on ►CONTRIVED◄ SAMPLES.”
My reply:
May 2020 was when the immunoglobulin (antibody) tests became available. It's good of CDC to admit the casedemic's cause and that there's no standard test to substantiate the PCR "test." If a single virus wasn't isolated, but instead its genetic sequence contrived by computer modeling based only on harmless viral debris, that debris might be from more than one germ and the patient could have multiple infections, contributing to a complex.
From CDC 2019-Novel Coronavirus (2019-nCoV) | Real-Time RT-PCR Diagnostic Panel | For Emergency Use Only | Instructions for Use (fda.gov/media/134922/download), under "Limitations:"
• Detection of viral RNA may not indicate the presence of infectious virus or that 2019-nCoV is the causative agent for clinical symptoms.
• The performance of this test has not been established for monitoring treatment of 2019-nCoV infection.
• The performance of this test has not been established for screening of blood or blood products for the presence of 2019-nCoV.
• This test cannot rule out diseases caused by other bacterial or viral pathogens."
• All users, analysts, and any person reporting diagnostic results should be trained to perform this procedure by a competent instructor. They should demonstrate their ability to perform the test and interpret the results prior to performing the assay independently.
• Performance of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel has only been established in upper and lower respiratory specimens (such as nasopharyngeal or oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate).
• Negative results do not preclude 2019-nCoV infection and should not be used as the sole basis for treatment or other patient management decisions. Optimum specimen types and timing for peak viral levels during infections caused by 2019-nCoV have not been determined. Collection of multiple specimens (types and time points) from the same patient may be necessary to detect the virus.
• A false-negative result may occur if a specimen is improperly collected, transported or handled. False-negative results may also occur if amplification inhibitors are present in the specimen or if inadequate numbers of organisms are present in the specimen.
• Positive and negative predictive values are highly dependent on prevalence. False-negative test results are more likely when prevalence of disease is high. False-positive test results are more likely when prevalence is moderate to low.
• Do not use any reagent past the expiration date.
• If the virus mutates in the rRT-PCR target region, 2019-nCoV may not be detected or may be detected less predictably. The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARSCoV-2 and their prevalence, which change over time.
• Inhibitors or other types of interference may produce a false-negative result. An interference study evaluating the effect of common cold medications was not performed.
• Test performance can be affected because the epidemiology and clinical spectrum of infection caused by 2019-nCoV is not fully known. For example, clinicians and laboratories may not know the optimum types of specimens to collect, and, during the course of infection, when these specimens are most likely to contain levels of viral RNA that can be readily detected.
• Detection of viral RNA may not indicate the presence of infectious virus or that 2019-nCoV is the causative agent for clinical symptoms.
• The performance of this test has not been established for monitoring treatment of 2019-nCoV infection.
• The performance of this test has not been established for screening of blood or blood products for the presence of 2019-nCoV.
• This test cannot rule out diseases caused by other bacterial or viral pathogens.
It's not hidden, just old news -- as most of this text is the same as over a year ago, as can be seen via WayBack Machine (archive.org) -- neglected by slavestream media.
Dr. Choe plans to address the Pinellas County Board of County Commissioners who are considering enacting a local emergency. This could include forced masking, expanded vaccine distribution (including schools) and other emergency powers. Come rally for MEDICAL HEALTH FREEDOM. Your liberty is being deliberated, and you need to prevent them from voting to restrict your freedom. We need people to rally at 8:30AM, and we need some people to go in and address the County Commission starting at 9:30AM"
Source: facebook.com/events/838310356818362
Frank Hopson wrote:
“You may have heard recently that the CDC has announced a change in the way it is testing for SARS-CoV-2:
'After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.' (Source: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data.)
The reason for the change is linked in the above announcement to this release by the FDA in late 2020 (emphasis mine):
'During the early months of the Coronavirus Disease 2019 (COVID-19) pandemic, clinical specimens [of the virus] were not readily available to developers of IVDs [in vitro diagnostics] to detect SARS-CoV-2. Therefore, the FDA authorized IVDs based on available data from ►CONTRIVED◄ samples generated from a range of SARS-CoV-2 material sources (for example, gene specific RNA, synthetic RNA, or whole genome viral RNA) for analytical and clinical performance evaluation. While validation using these ►CONTRIVED◄ specimens provided a measure of confidence in test performance at the beginning of the pandemic, it is not feasible to precisely compare the performance of various tests that used ►CONTRIVED◄ specimens because each test validated performance using samples derived from different gene specific, synthetic, or genomic nucleic acid sources.' (Source: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data.)
It goes on to say:
'From February through the middle of May, the FDA issued a total of 59 EUAs for IVDs for the qualitative detection of nucleic acid from SARS-CoV-2 based on validation data using ►contrived◄ specimens derived from SARS-CoV-2 viral RNA. As the pandemic progressed and more patient specimens became available, on May 11, 2020, the FDA recommended in the Policy for Coronavirus Disease-2019 Tests that developers obtain and use patient specimens to validate their tests.'
If you follow the link in that paragraph and go to page 18 of that non-binding policy paper, under '(2) Clinical Evaluation,' it says:
'The availability of positive samples has increased as the pandemic has progressed. As such, FDA now recommends that developers use positive clinical samples for clinical validation. Moreover, due to the increased availability of clinical samples, FDA recommends that developers confirm performance of their assay by testing a minimum of 30 positive specimens and 30 negative specimens as determined by an authorized assay. If you do not have access to clinical samples as determined by an authorized assay, ►CONTRIVED◄ clinical specimens may be considered. ►CONTRIVED◄ reactive specimens can be created by spiking RNA or inactivated virus into leftover clinical specimens, of which the majority can be leftover upper respiratory specimens such as NP swabs, or lower respiratory tract specimens such as sputum, etc. If ►CONTRIVED◄ samples are used, FDA recommends that twenty of the ►CONTRIVED◄ clinical specimens be spiked at a concentration of 1x2x LoD, with the remainder of specimens spanning the assay testing range. For this guidance, FDA defines the acceptance criteria for the performance as 95% agreement at 1x-2x LoD, and 100% agreement at all other concentrations and for negative specimens.' (Source: https://www.fda.gov/media/135659/download)
So after May 2020, ►contrived◄ samples were still allowed and will be allowed up until the last day of this year.
So what this is saying is the all COVID testing from February 2020 through May 2020 and however much testing until the end of the year is based on ►CONTRIVED◄ SAMPLES.”
My reply:
May 2020 was when the immunoglobulin (antibody) tests became available. It's good of CDC to admit the casedemic's cause and that there's no standard test to substantiate the PCR "test." If a single virus wasn't isolated, but instead its genetic sequence contrived by computer modeling based only on harmless viral debris, that debris might be from more than one germ and the patient could have multiple infections, contributing to a complex.
From CDC 2019-Novel Coronavirus (2019-nCoV) | Real-Time RT-PCR Diagnostic Panel | For Emergency Use Only | Instructions for Use (fda.gov/media/134922/download), under "Limitations:"
• Detection of viral RNA may not indicate the presence of infectious virus or that 2019-nCoV is the causative agent for clinical symptoms.
• The performance of this test has not been established for monitoring treatment of 2019-nCoV infection.
• The performance of this test has not been established for screening of blood or blood products for the presence of 2019-nCoV.
• This test cannot rule out diseases caused by other bacterial or viral pathogens."
• All users, analysts, and any person reporting diagnostic results should be trained to perform this procedure by a competent instructor. They should demonstrate their ability to perform the test and interpret the results prior to performing the assay independently.
• Performance of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel has only been established in upper and lower respiratory specimens (such as nasopharyngeal or oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate).
• Negative results do not preclude 2019-nCoV infection and should not be used as the sole basis for treatment or other patient management decisions. Optimum specimen types and timing for peak viral levels during infections caused by 2019-nCoV have not been determined. Collection of multiple specimens (types and time points) from the same patient may be necessary to detect the virus.
• A false-negative result may occur if a specimen is improperly collected, transported or handled. False-negative results may also occur if amplification inhibitors are present in the specimen or if inadequate numbers of organisms are present in the specimen.
• Positive and negative predictive values are highly dependent on prevalence. False-negative test results are more likely when prevalence of disease is high. False-positive test results are more likely when prevalence is moderate to low.
• Do not use any reagent past the expiration date.
• If the virus mutates in the rRT-PCR target region, 2019-nCoV may not be detected or may be detected less predictably. The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARSCoV-2 and their prevalence, which change over time.
• Inhibitors or other types of interference may produce a false-negative result. An interference study evaluating the effect of common cold medications was not performed.
• Test performance can be affected because the epidemiology and clinical spectrum of infection caused by 2019-nCoV is not fully known. For example, clinicians and laboratories may not know the optimum types of specimens to collect, and, during the course of infection, when these specimens are most likely to contain levels of viral RNA that can be readily detected.
• Detection of viral RNA may not indicate the presence of infectious virus or that 2019-nCoV is the causative agent for clinical symptoms.
• The performance of this test has not been established for monitoring treatment of 2019-nCoV infection.
• The performance of this test has not been established for screening of blood or blood products for the presence of 2019-nCoV.
• This test cannot rule out diseases caused by other bacterial or viral pathogens.
It's not hidden, just old news -- as most of this text is the same as over a year ago, as can be seen via WayBack Machine (archive.org) -- neglected by slavestream media.
Bumper Music
|
Opening first hour: Show introduction with clips from If by Freemasons featuring Hazel Fernandes, Another Night by Alex Christensen & The Berlin Orchestra, featuring Anastacia, Radio by Jamiroquai, Call Me by Aretha Franklin, Sick and Tired by Anastacia, Weapon Of Choice by Fatboy Slim featuring Bootsy Collins, and The Way I See It by Anastacia
Closing first hour: Rush - Vital Signs Opening second hour: Mike Adams - Vaccine Zombie Closing second hour: Anastacia - Higher Livin' |
|
